PHASE II/III & THERAPEUTIC EVIDENCE

How do CROs differ on Phase II/III and therapeutic focus?

Global CROs market multi-phase execution, while specialists concentrate on specific indications or delivery settings. Every figure below keeps its stated scope restriction—such as office counts versus active clinical sites, overlapping percentages, and ICON’s Accellacare in-home restriction.

IQVIA

Phase claim: Phase IIb/III Trials (Vendor service page claim; this title establishes a marketed Phase IIb/III offering only, not study-specific experience, performance or suitability.)

Therapeutic focus: Includes oncology/hematology, CNS, rare disease, obesity and cell/gene therapy. Company-wide claim; ask for matching study references and a named available team. Source & date

Offices, labs & site footprint: Office/site footprint not quantified on reviewed page

ICON plc

Phase claim: Phase 2–3 clinical operations Company-wide claim; ask for matching study references and a named available team. Source & date

Therapeutic focus: Cardio-metabolic, oncology/hematology, infection, neurology/psychiatry, rare disease, respiratory and biosimilars. Company-wide claim; ask for matching study references and a named available team. Source & date

Offices, labs & site footprint: Office/site footprint not quantified on reviewed page

Medpace

Phase claim: all phases of development (including wholly-owned Phase I Unit) (Vendor homepage claim; does not establish indication-specific trial counts or study outcomes.)

Therapeutic focus: Includes oncology/hematology, endocrine/metabolic, neuroscience, immunology and rare disease. Company-wide claim; ask for matching study references and a named available team. Source & date

Offices, labs & site footprint: Cincinnati, Ohio US headquarters; 33 offices across 46 countries (6,600 employees) (Company-reported headcount/office footprint; does not establish active clinical trial sites in a therapeutic area.)

Parexel

Phase claim: Phase IIb-IV clinical trials (Vendor service page claim; does not establish study-specific experience or team assignments.)

Therapeutic focus: General medicine, infectious disease and vaccines, immunology, neuroscience (Vendor-listed therapeutic areas on integrated clinical development page; additional therapeutic areas may appear on separate pages.)

Offices, labs & site footprint: Raleigh, North Carolina US address listed (US office address on service page; global site reach depends on Site Alliance Network.)

Syneos Health

Phase claim: all phases including Early Phase, Phase II-IV and Real World Evidence (Vendor capability claim; does not establish study-specific outcomes.)

Therapeutic focus: oncology and hematology, neuroscience, rare disease, dermatology (Vendor claim; self-reported ~70% biotech customer portfolio.)

Offices, labs & site footprint: Office/site footprint not quantified on reviewed page

Fortrea

Phase claim: Not stated on reviewed page

Therapeutic focus: Not enumerated on reviewed page

Offices, labs & site footprint: 15,000+ investigators and 5,500+ sites in global network (counts not broken out by US vs ex-US) (Company-reported global site/investigator network; US share not separated on page.)

Thermo Fisher Scientific, PPD clinical services

Phase claim: early development, all phases of clinical development, peri- and post-approval (Vendor brand overview claim across multiple therapeutic areas.)

Therapeutic focus: Not enumerated on reviewed page

Offices, labs & site footprint: Office/site footprint not quantified on reviewed page

Labcorp Drug Development

Phase claim: Not stated on reviewed page

Therapeutic focus: Not enumerated on reviewed page

Offices, labs & site footprint: Madison, Wisconsin and Indianapolis, Indiana flagship US labs plus specialty US labs (US laboratory locations; does not establish clinical trial site operations.)

Worldwide Clinical Trials

Phase claim: Phase I-IIa, Phase II-IV (specializing in Phase IIb-IV peri-approval), RWE, and Transition Studies (Vendor capability claim; specific therapeutic indications sit on separate subpages.)

Therapeutic focus: Not enumerated on reviewed page

Offices, labs & site footprint: Office/site footprint not quantified on reviewed page

Precision for Medicine

Phase claim: Early Phase (first-in-human through Phase 2a) and Late Phase (Phase 2b-4 pivotal) (Vendor capability claim.)

Therapeutic focus: Oncology & immuno-oncology (stated 76% of trials), rare & orphan diseases (stated 67% of trials), autoimmune, cell/gene therapy (Vendor self-reported trial percentages; percentages overlap because trials can be both oncology and rare disease.)

Offices, labs & site footprint: 20 offices and 2,350 experts across the Americas (US vs ex-US split not detailed) (Regional Americas footprint; Precision Site Network provides academic medical center access.)

Veristat

Phase claim: complex Phase I-III clinical development (Vendor service claim.)

Therapeutic focus: rare disease trial delivery and complex specialty programs (Vendor lists rare disease and natural history trial delivery; other indications not enumerated on page.)

Offices, labs & site footprint: Office/site footprint not quantified on reviewed page

Indero

Phase claim: early and late phase clinical trials (Vendor capability claim (formerly Innovaderm).)

Therapeutic focus: dual-focus dermatology (30+ indications) and rheumatology (20+ indications) (Specialty dual-focus CRO; North America CRU operates as Innovaderm.)

Offices, labs & site footprint: Office/site footprint not quantified on reviewed page

Kapadi

Phase claim: Not stated on reviewed page

Therapeutic focus: oncology (solid and liquid malignancies, immuno-oncology) and cell & gene therapies (common and rare indications) (Vendor specialty positioning; notes partnership/historic connection to Moffitt Cancer Center.)

Offices, labs & site footprint: Raleigh, North Carolina US registered office; North America specialty oncology site network (US registered office and North American network claim.)

PharPoint

Phase claim: Phase II-IV clinical trials (Vendor service page claim.)

Therapeutic focus: Not enumerated on reviewed page

Offices, labs & site footprint: Durham, NC and Wilmington, NC offices; experience working with locations across the United States (US offices and stated US location experience.)

Proxima CRO

Phase claim: Not stated on reviewed page

Therapeutic focus: Not enumerated on reviewed page

Offices, labs & site footprint: Houston, Texas US office (US office address; trial site footprint not detailed on homepage.)

What to verify in your Phase II/III RFI

← Back to the 16-CRO overview

Broader pages fill three early shortlist gaps

These pages describe general capabilities. They still need a protocol-specific match.

IQVIA · therapeutic scope

IQVIA’s FAQ names allergy/respiratory, biosimilars, cardiovascular, cell/gene therapy, CNS, dermatology, endocrinology, GI/hepatology, infection/vaccines, nephrology, obesity, oncology/hematology, ophthalmology, pediatrics, rare disease, reproductive health and rheumatology.

This is a company-wide list of marketed expertise. It supplies no indication-specific trial count, proposed team or recruitment result. Source & date

ICON · general operations

ICON’s Clinical and Scientific Operations page explicitly covers planning, managing, running and analysing Phase 2–3 trials.

This general clinical-operations claim is broader than its separate Accellacare in-home page. It is not proof of success in your protocol. Source & date

ICON names cardio-metabolic, oncology/hematology, infectious disease, neurology/psychiatry, rare disease, respiratory and biosimilars.

Company-wide therapeutic expertise; confirm the exact indication and proposed staff’s experience. Source & date

Medpace · therapeutic scope

Medpace’s FAQ covers cardiovascular, dermatology, endocrine/metabolic, GI/hepatology, immunology/inflammation, infection/vaccines, nephrology, neuroscience, oncology/hematology, ophthalmology, respiratory and rheumatology. It also names rare disease, pediatrics, cell/gene therapy and other crossovers.

The FAQ describes Phase I–IV support. This is not a count of recent trials, US sites or staff available for a specific indication. Source & date